Ganina C.A., Mahonin A.A., Vladimirova T.Ju. Current perspectives and treatment options for anaplastic thyroid cancer . Head and neck. Russian Journal. 2023;11(1):85–92
The authors are responsible for the originality of the data presented and the possibility of publishing illustrative material – tables, drawings, photographs of patients.
Anaplastic thyroid cancer (TC) is one of the rarest and deadliest human malignancies. The low incidence of anaplastic TC created difficulties in the complex genomic characterization of this tumor, as a result of which new treatment approaches were not lacking for a long time. Over the past decade, anaplastic TC studies have involved sequencing to determine the genetic landscape of this tumor and identify new therapeutic targets. With the advent of new molecular tests and improvements in diagnostic methods, new targets for drug therapy have been identified. This fact has led to a rapidly expanding understanding of the molecular basis of anaplastic TR, providing the basis for targeted therapies, including BRAF inhibitors and drugs acting on immune checkpoints PD-1 (programmed death-1)/PD-L1 (programmed death-ligand 1). This review describes the molecular changes that occur in anaplastic TC, with an emphasis on those that are already being investigated and may also affect treatment strategy.
Key words: thyroid cancer, targeted therapy, tyrosine kinase inhibitors, immunotherapy
Conflicts of interest. The authors have no conflicts of interest to declare.
Funding. There was no funding for this study